Skip to content

TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY One-Year Results

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Citation
Web of Science 14
JCR IF
JCR 2016 3.7
ISSN
0275-004X

Authors

  1. Pak, Gang YunFirst authorMedical Research Institute, Pusan National University Hospital, Busan, South Korea
  2. Park, Sung-whoMedical Research Institute, Pusan National University Hospital, Busan, South Korea
  3. Byon, IksooResearch Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea
  4. Lee, Ji-EunCorresponding authorMedical Research Institute, Pusan National University Hospital, Busan, South Korea

Abstract

Purpose: To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose $ 3 best-corrected visual acuity (BCVA) lines. The number of intravitreal injections and recurrences as well as the maximum treatment interval without recurrence were analyzed. Results: The mean BCVA improved from 0.64 +/- 0.42 logMAR (median, 20/80) at baseline to 0.30 +/- 0.31 logMAR (median, 20/30) at 12 months (P < 0.001). The mean central subfield macular thickness improved from 307.0 +/- 70.2 mu m to 237.5 +/- 64.4 mu m (P < 0.001). None of the subjects lost $ 3 lines, and 15 (51.7%) gained >= 3 lines. The mean number of injections was 7.0. The mean maximum treatment interval without recurrence was 10.0 weeks. After the loading phase, 12 eyes (41.4%) showed no recurrence. Seven eyes (24.1%) demonstrated disease activity at 12 months, and 4 (13.8%) of them were never dry during the entire 12-month follow-up duration. Conclusion: The TER effectively improved visual acuity in PCV while reducing the number of injections.

Keywords

polypoidal choroidal vasculopathytreat-and-extendVERTEPORFIN PHOTODYNAMIC THERAPYMACULAR DEGENERATION

Identifiers

WoS UID
000397987600030